Logo image of AIM

AIM IMMUNOTECH INC (AIM) Stock Fundamental Analysis

NYSEARCA:AIM - NYSE Arca - US00901B1052 - Common Stock - Currency: USD

9.21  +0.91 (+10.96%)

Fundamental Rating

1

AIM gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 557 industry peers in the Biotechnology industry. Both the profitability and financial health of AIM have multiple concerns. AIM is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AIM has reported negative net income.
AIM had a negative operating cash flow in the past year.
AIM had negative earnings in each of the past 5 years.
AIM had a negative operating cash flow in each of the past 5 years.
AIM Yearly Net Income VS EBIT VS OCF VS FCFAIM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

AIM has a worse Return On Assets (-176.10%) than 86.84% of its industry peers.
With a Return On Equity value of -821.74%, AIM is not doing good in the industry: 81.75% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -176.1%
ROE -821.74%
ROIC N/A
ROA(3y)-76.87%
ROA(5y)-59.64%
ROE(3y)-122.39%
ROE(5y)-92.13%
ROIC(3y)N/A
ROIC(5y)N/A
AIM Yearly ROA, ROE, ROICAIM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150 -200 -250

1.3 Margins

The Gross Margin of AIM (81.05%) is better than 85.26% of its industry peers.
AIM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 81.05%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AIM Yearly Profit, Operating, Gross MarginsAIM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -5K -10K -15K

More info and screens

1

2. Health

2.1 Basic Checks

AIM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AIM has been increased compared to 1 year ago.
AIM has more shares outstanding than it did 5 years ago.
There is no outstanding debt for AIM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AIM Yearly Shares OutstandingAIM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
AIM Yearly Total Debt VS Total AssetsAIM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

AIM has an Altman-Z score of -49.97. This is a bad value and indicates that AIM is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of AIM (-49.97) is worse than 93.68% of its industry peers.
A Debt/Equity ratio of 0.05 indicates that AIM is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.05, AIM is doing worse than 62.46% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -49.97
ROIC/WACCN/A
WACC10.65%
AIM Yearly LT Debt VS Equity VS FCFAIM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 0.75 indicates that AIM may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.75, AIM is doing worse than 90.88% of the companies in the same industry.
AIM has a Quick Ratio of 0.75. This is a bad value and indicates that AIM is not financially healthy enough and could expect problems in meeting its short term obligations.
AIM's Quick ratio of 0.75 is on the low side compared to the rest of the industry. AIM is outperformed by 90.70% of its industry peers.
Industry RankSector Rank
Current Ratio 0.75
Quick Ratio 0.75
AIM Yearly Current Assets VS Current LiabilitesAIM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for AIM have decreased strongly by -12.56% in the last year.
The Revenue has decreased by -1.55% in the past year.
Measured over the past years, AIM shows a very negative growth in Revenue. The Revenue has been decreasing by -11.26% on average per year.
EPS 1Y (TTM)-12.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
Revenue 1Y (TTM)-1.55%
Revenue growth 3Y7.41%
Revenue growth 5Y-11.26%
Sales Q2Q%-23.91%

3.2 Future

The Earnings Per Share is expected to grow by 12.45% on average over the next years. This is quite good.
Based on estimates for the next years, AIM will show a very strong growth in Revenue. The Revenue will grow by 217.99% on average per year.
EPS Next Y41.93%
EPS Next 2Y17.35%
EPS Next 3Y7.02%
EPS Next 5Y12.45%
Revenue Next Year-7.64%
Revenue Next 2Y306.95%
Revenue Next 3Y262.84%
Revenue Next 5Y217.99%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AIM Yearly Revenue VS EstimatesAIM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
AIM Yearly EPS VS EstimatesAIM Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AIM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AIM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AIM Price Earnings VS Forward Price EarningsAIM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AIM Per share dataAIM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.35%
EPS Next 3Y7.02%

More info and screens

0

5. Dividend

5.1 Amount

AIM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AIM IMMUNOTECH INC

NYSEARCA:AIM (6/20/2025, 5:05:00 PM)

9.21

+0.91 (+10.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-07 2025-04-07/amc
Earnings (Next)05-14 2025-05-14
Inst Owners7.29%
Inst Owner Change3.95%
Ins Owners9.54%
Ins Owner Change7.61%
Market Cap665.79M
Analysts80
Price Target2.81 (-69.49%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)52.26%
Min EPS beat(2)36.63%
Max EPS beat(2)67.89%
EPS beat(4)2
Avg EPS beat(4)7.4%
Min EPS beat(4)-71.62%
Max EPS beat(4)67.89%
EPS beat(8)5
Avg EPS beat(8)6.16%
EPS beat(12)5
Avg EPS beat(12)-7.26%
EPS beat(16)6
Avg EPS beat(16)-9.26%
Revenue beat(2)2
Avg Revenue beat(2)211.11%
Min Revenue beat(2)98.02%
Max Revenue beat(2)324.21%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.17%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.47%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)48.15%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3504.16
P/FCF N/A
P/OCF N/A
P/B 228.64
P/tB 1752.08
EV/EBITDA N/A
EPS(TTM)-0.48
EYN/A
EPS(NY)-0.37
Fwd EYN/A
FCF(TTM)-0.29
FCFYN/A
OCF(TTM)-0.29
OCFYN/A
SpS0
BVpS0.04
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -176.1%
ROE -821.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 81.05%
FCFM N/A
ROA(3y)-76.87%
ROA(5y)-59.64%
ROE(3y)-122.39%
ROE(5y)-92.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 90%
Cap/Sales 113.68%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.75
Quick Ratio 0.75
Altman-Z -49.97
F-Score2
WACC10.65%
ROIC/WACCN/A
Cap/Depr(3y)144.45%
Cap/Depr(5y)112.12%
Cap/Sales(3y)316.9%
Cap/Sales(5y)315.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
EPS Next Y41.93%
EPS Next 2Y17.35%
EPS Next 3Y7.02%
EPS Next 5Y12.45%
Revenue 1Y (TTM)-1.55%
Revenue growth 3Y7.41%
Revenue growth 5Y-11.26%
Sales Q2Q%-23.91%
Revenue Next Year-7.64%
Revenue Next 2Y306.95%
Revenue Next 3Y262.84%
Revenue Next 5Y217.99%
EBIT growth 1Y-18.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-30.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.09%
OCF growth 3YN/A
OCF growth 5YN/A